Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors.
Aromatase inhibitors
Bisphosphonates
Denosumab
Trabecular bone score
Vertebral fractures
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
17 Aug 2023
17 Aug 2023
Historique:
received:
14
06
2023
accepted:
03
08
2023
pubmed:
18
8
2023
medline:
18
8
2023
entrez:
17
8
2023
Statut:
aheadofprint
Résumé
Trabecular bone score (TBS) is a gray-level textural metric that has shown to correlate with risk of fractures in several forms of osteoporosis. The value of TBS in predicting fractures and the effects of bone-active drugs on TBS in aromatase inhibitors (AIs)-induced osteoporosis are still largely unknown. The primary objective of this retrospective study was to assess the effects of denosumab and bisphosphonates (BPs) on TBS and vertebral fractures (VFs) in women exposed to AIs. 241 consecutive women (median age 58 years) with early breast cancer undergoing treatment with AIs were evaluated for TBS, bone mineral density (BMD) and morphometric VFs at baseline and after 18-24 months of follow-up. During the study period, 139 women (57.7%) received denosumab 60 mg every 6 months, 53 (22.0%) BPs, whereas 49 women (20.3%) were not treated with bone-active drugs. Denosumab significantly increased TBS values (from 1.270 to 1.323; P < 0.001) accompanied by a significant decrease in risk of VFs (odds ratio 0.282; P = 0.021). During treatment with BPs, TBS did not significantly change (P = 0.849) and incidence of VFs was not significantly different from women untreated with bone-active drugs (P = 0.427). In the whole population, women with incident VFs showed higher decrease in TBS vs. non-fractured women (P = 0.003), without significant differences in changes of BMD at any skeletal site. TBS variation predicts fracture risk in AIs treated women. Denosumab is effective to induce early increase of TBS and reduction in risk of VFs.
Identifiants
pubmed: 37592052
doi: 10.1007/s40618-023-02174-5
pii: 10.1007/s40618-023-02174-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017) Management of aromatase inhibitor-associated bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12. https://doi.org/10.1016/j.jbo.2017.03.001
doi: 10.1016/j.jbo.2017.03.001
pubmed: 28413771
pmcid: 5384888
EBCTCG (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352. https://doi.org/10.1016/S0140-6736(15)61074-1
doi: 10.1016/S0140-6736(15)61074-1
Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123(10):877–884. https://doi.org/10.1016/j.amjmed.2010.02.028
doi: 10.1016/j.amjmed.2010.02.028
pubmed: 20920685
Cianferotti L, Cipriani C, Corbetta S, Corona G, Defeudis G, Lania AG, Messina C, Napoli N, Mazziotti G (2023) Bone quality in endocrine diseases: determinants and clinical relevance. J Endocrinol Invest 46(7):1283–1304. https://doi.org/10.1007/s40618-023-02056-w
doi: 10.1007/s40618-023-02056-w
pubmed: 36918505
Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69(1):73–82. https://doi.org/10.1016/j.critrevonc.2008.07.013
doi: 10.1016/j.critrevonc.2008.07.013
pubmed: 18757208
Pedersini R, Cosentini D, Rinaudo L, Zamparini M, Ulivieri FM, di Mauro P, Maffezzoni F, Monteverdi S, Vena W, Laini L, Amoroso V, Simoncini EL, Farina D, Mazziotti G, Berruti A (2023) Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: a single center cross-sectional study. Bone Rep 18:101654. https://doi.org/10.1016/j.bonr.2023.101654
doi: 10.1016/j.bonr.2023.101654
pubmed: 36700242
pmcid: 9868326
Krohn K, Schwartz EN, Chung YS, Lewiecki EM (2019) Dual-energy X-ray absorptiometry monitoring with trabecular bone score: 2019 ISCD Official Position. J Clin Densitom 22(4):501–505. https://doi.org/10.1016/j.jocd.2019.07.006
doi: 10.1016/j.jocd.2019.07.006
pubmed: 31383412
Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA (2011) Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom 14(3):302–312. https://doi.org/10.1016/j.jocd.2011.05.005
doi: 10.1016/j.jocd.2011.05.005
pubmed: 21724435
Palomo T, Muszkat P, Weiler FG, Dreyer P, Brandão CMA, Silva BC (2022) Update on trabecular bone score. Arch Endocrinol Metab 66(5):694–706. https://doi.org/10.20945/2359-3997000000559
doi: 10.20945/2359-3997000000559
pubmed: 36382759
pmcid: 10118821
Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28(4):1413–1422. https://doi.org/10.1007/s00198-016-3899-6
doi: 10.1007/s00198-016-3899-6
pubmed: 28083668
Catalano A, Gaudio A, Agostino RM, Morabito N, Bellone F, Lasco A (2019) Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors. J Endocrinol Invest 42(11):1337–1343. https://doi.org/10.1007/s40618-019-01063-0
doi: 10.1007/s40618-019-01063-0
pubmed: 31127591
Pedrazzoni M, Casola A, Verzicco I, Abbate B, Vescovini R, Sansoni P (2014) Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition. J Endocrinol Invest 37(9):871–874. https://doi.org/10.1007/s40618-014-0125-2
doi: 10.1007/s40618-014-0125-2
pubmed: 25037472
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37(31):2916–2946. https://doi.org/10.1200/jco.19.01696
doi: 10.1200/jco.19.01696
pubmed: 31532726
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X
doi: 10.1016/S0140-6736(07)61602-X
Rossini M, Adami S, Bertoldo F, Diacinti D, Gatti D, Giannini S, Giusti A, Malavolta N, Minisola S, Osella G, Pedrazzoni M, Sinigaglia L, Viapiana O, Isaia GC (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68(1):1–39. https://doi.org/10.4081/reumatismo.2016.870
doi: 10.4081/reumatismo.2016.870
pubmed: 27339372
Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, Maroldi R, Berruti A (2020) Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol 38(29):3363–3366. https://doi.org/10.1200/JCO.20.00434
doi: 10.1200/JCO.20.00434
pubmed: 32603244
Mazziotti G, Vena W, Pedersini R, Piccini S, Morenghi E, Cosentini D, Zucali P, Torrisi R, Sporeni S, Simoncini EL, Maroldi R, Balzarini L, Lania AG, Berruti A (2022) Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice. J Bone Oncol 33:100421. https://doi.org/10.1016/j.jbo.2022.100421
doi: 10.1016/j.jbo.2022.100421
pubmed: 35310388
pmcid: 8928084
Clark EM, Carter L, Gould VC, Morrison L, Tobias JH (2014) Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening. Osteoporos Int 25(3):953–964. https://doi.org/10.1007/s00198-013-2567-3
doi: 10.1007/s00198-013-2567-3
pubmed: 24292107
Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42(1):39–51. https://doi.org/10.1007/s12020-012-9691-2
doi: 10.1007/s12020-012-9691-2
pubmed: 22618377
Engelke K, Stampa B, Steiger P, Fuerst T, Genant HK (2019) Automated quantitative morphometry of vertebral heights on spinal radiographs: comparison of a clinical workflow tool with standard 6-point morphometry. Arch Osteoporos 14(1):18. https://doi.org/10.1007/s11657-019-0577-2
doi: 10.1007/s11657-019-0577-2
pubmed: 30741350
Crans GG, Genant HK, Krege JH (2005) Prognostic utility of a semiquantitative spinal deformity index. Bone 37(2):175–179. https://doi.org/10.1016/j.bone.2005.04.003
doi: 10.1016/j.bone.2005.04.003
pubmed: 15922683
Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International society for clinical densitometry position development conference on bone densitometry. J Clin Densitom 16(4):455–466. https://doi.org/10.1016/j.jocd.2013.08.004
doi: 10.1016/j.jocd.2013.08.004
pubmed: 24183638
McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJM, Fujita Y, Glüer CC, Goltzman D, Iki M, Karlsson M, Kindmark A, Kotowicz M, Kurumatani N, Kwok T, Lamy O, Leung J, Lippuner K, Ljunggren Ö, Lorentzon M, Mellström D, Merlijn T, Oei L, Ohlsson C, Pasco JA, Rivadeneira F, Rosengren B, Sornay-Rendu E, Szulc P, Tamaki J, Kanis JA (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31(5):940–948. https://doi.org/10.1002/jbmr.2734
doi: 10.1002/jbmr.2734
pubmed: 26498132
Adami G, Biffi A, Porcu G, Ronco R, Alvaro R, Bogini R, Caputi AP, Cianferotti L, Frediani B, Gatti D, Gonnelli S, Iolascon G, Lenzi A, Leone S, Migliaccio S, Nicoletti T, Paoletta M, Pennini A, Piccirilli E, Tarantino U, Brandi ML, Corrao G, Rossini M, Michieli R (2023) A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS. J Endocrinol Investig. https://doi.org/10.1007/s40618-023-02082-8
doi: 10.1007/s40618-023-02082-8
Bertoldo F, Cianferotti L, Di Monaco M, Falchetti A, Fassio A, Gatti D, Gennari L, Giannini S, Girasole G, Gonnelli S, Malavolta N, Minisola S, Pedrazzoni M, Rendina D, Rossini M, Chiodini I (2022) Definition, assessment, and management of vitamin D inadequacy : suggestions, recommendations, and warnings from the Italian society for osteoporosis, mineral metabolism and bone diseases (SIOMMMS). Nutrients. https://doi.org/10.3390/nu14194148
doi: 10.3390/nu14194148
pubmed: 36235800
pmcid: 9573415
Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, Omar RZ (2015) How to develop a more accurate risk prediction model when there are few events. BMJ 351:h3868. https://doi.org/10.1136/bmj.h3868
doi: 10.1136/bmj.h3868
pubmed: 26264962
pmcid: 4531311
Gates M, Pillay J, Nuspl M, Wingert A, Vandermeer B, Hartling L (2023) Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools. Syst Rev 12(1):51. https://doi.org/10.1186/s13643-023-02181-w
doi: 10.1186/s13643-023-02181-w
pubmed: 36945065
pmcid: 10029308
Lu H, Lei X, Zhao H, Elting L, Siricilla M, Ursani MA, Giordano SH, Suarez-Almazor M (2021) Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer. J Bone Miner Res 36(5):861–871. https://doi.org/10.1002/jbmr.4250
doi: 10.1002/jbmr.4250
pubmed: 33484602
Mazziotti G, Pedersini R, Vena W, Cosentini D, Carrone F, Pigni S, Simoncini EL, Torrisi R, Zambelli A, Farina D, Balzarini L, Lania AG, Berruti A (2022) Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral Fractures in women with breast cancer undergoing treatment with aromatase inhibitors. Calcif Tissue Int 111(5):466–474. https://doi.org/10.1007/s00223-022-01011-w
doi: 10.1007/s00223-022-01011-w
pubmed: 35902384
McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C (2017) Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporosis Int 28(10):2967–2973. https://doi.org/10.1007/s00198-017-4140-y
doi: 10.1007/s00198-017-4140-y
Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25(7):1945–1951. https://doi.org/10.1007/s00198-014-2703-8
doi: 10.1007/s00198-014-2703-8
pubmed: 24760244
Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B (2023) Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: post hoc analysis of ACTIVE and ACTIVExtend. J Bone Miner Res. https://doi.org/10.1002/jbmr.4764
doi: 10.1002/jbmr.4764
pubmed: 37706244
Jeong C, Kim J, Lim Y, Ha J, Kang MI, Baek KH (2022) Effect of romosozumab on trabecular bone score compared to anti-resorptive agents in postmenopausal women with osteoporosis. J Bone Metab 29(4):279. https://doi.org/10.11005/jbm.2022.29.4.279
doi: 10.11005/jbm.2022.29.4.279
pubmed: 36529871
pmcid: 9760771
Rodríguez-Sanz MP-MM, Servitja S, Garcia-Giralt N, Martos T, Tusquets I, Martínez-García M, Rodriguez-M D-P, Albanell J, Nogués X (2016) TBS and BMD at the end of AI-therapy: a prospective study of the B-ABLE cohort. Bone 92:1–8. https://doi.org/10.1016/j.bone.2016.08.008
doi: 10.1016/j.bone.2016.08.008
Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S (2016) Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: a randomized, controlled clinical trial. Bone 90:123–126. https://doi.org/10.1016/j.bone.2016.03.010
doi: 10.1016/j.bone.2016.03.010
pubmed: 27018037
Iconaru LBF, Charles A, Mugisha A, Benoit F, Surquin M, Karmali R, Body JJ, Bergmann P (2021) Which treatment to prevent an imminent fracture? Bone Rep 15:101105. https://doi.org/10.1016/j.bonr.2021.101105
doi: 10.1016/j.bonr.2021.101105
Hu YJ, Chines A, Shi Y, Seeman E, Guo XE (2022) The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: a post-hoc HR-pQCT study. Bone 154:116187. https://doi.org/10.1016/j.bone.2021.116187
doi: 10.1016/j.bone.2021.116187
pubmed: 34530172
Dempster DW, Chines A, Bostrom MP, Nieves JW, Zhou H, Chen L, Pannacciulli N, Wagman RB, Cosman F (2020) Modeling-based bone formation in the human femoral neck in subjects treated with denosumab. J Bone Miner Res 35(7):1282–1288. https://doi.org/10.1002/jbmr.4006
doi: 10.1002/jbmr.4006
pubmed: 32163613
De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ 3rd, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16(11):1330–1338. https://doi.org/10.1007/s00198-005-1863-y
doi: 10.1007/s00198-005-1863-y
pubmed: 15928804
Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, Formenti AM, Dalla Volta A, Simoncini EL, Giustina A, Maroldi R, Berruti A (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open 2(9):e1911080. https://doi.org/10.1001/jamanetworkopen.2019.11080
doi: 10.1001/jamanetworkopen.2019.11080
pubmed: 31560383
pmcid: 6777242
Monteverdi S, Pedersini R, Gallo F, Maffezzoni F, Dalla Volta A, Di Mauro P, Turla A, Vassalli L, Ardine M, Formenti AM, Simoncini EL, Giustina A, Maroldi R, Amoroso V, Berruti A (2021) The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy. JBMR Plus 5(2):e10440. https://doi.org/10.1002/jbm4.10440
doi: 10.1002/jbm4.10440
pubmed: 33615109
Diacinti D, Del Fiacco R, Pisani D, Todde F, Cattaruzza MS, Diacinti D, Arima S, Romagnoli E, Pepe J, Cipriani C, Minisola S (2012) Diagnostic performance of vertebral fracture assessment by the lunar iDXA scanner compared to conventional radiography. Calcif Tissue Int 91(5):335–342. https://doi.org/10.1007/s00223-012-9643-0
doi: 10.1007/s00223-012-9643-0
pubmed: 22965625
Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD (2007) Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41(3):346–352. https://doi.org/10.1016/j.bone.2007.06.004
doi: 10.1016/j.bone.2007.06.004
pubmed: 17618847
Szulc P (2018) Bone turnover: biology and assessment tools. Best Pract Res Clin Endocrinol Metab 32(5):725–738. https://doi.org/10.1016/j.beem.2018.05.003
doi: 10.1016/j.beem.2018.05.003
pubmed: 30449551
Vena W, Carrone F, Delbarba A, Akpojiyovbi O, Pezzaioli LC, Facondo P, Cappelli C, Leonardi L, Balzarini L, Farina D, Pizzocaro A, Lania AG, Mazziotti G, Ferlin A (2023) Body composition, trabecular bone score and vertebral fractures in subjects with Klinefelter syndrome. J Endocrinol Invest 46(2):297–304. https://doi.org/10.1007/s40618-022-01901-8
doi: 10.1007/s40618-022-01901-8
pubmed: 36030302
Dalla Volta A, Palumbo C, Zamboni S, Mazziotti G, Triggiani L, Zamparini M, Maffezzoni F, Rinaudo L, Bergamini M, Di Meo N, Caramella I, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Berruti A (2023) Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study. J Endocrinol Invest. https://doi.org/10.1007/s40618-023-02150-z
doi: 10.1007/s40618-023-02150-z
pubmed: 37458931
Amnuaywattakorn S, Sritara C, Utamakul C, Chamroonrat W, Kositwattanarerk A, Thamnirat K, Ongphiphadhanakul B (2016) Simulated increased soft tissue thickness artefactually decreases trabecular bone score: a phantom study. BMC Musculoskelet Disord 17:17. https://doi.org/10.1186/s12891-016-0886-1
doi: 10.1186/s12891-016-0886-1
pubmed: 26757709
pmcid: 4710977
Hans D, Shevroja E, McDermott M, Huang S, Kim M, McClung M (2022) Updated trabecular bone score accounting for the soft tissue thickness (TBS(TT)) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis. Osteoporos Int 33(12):2517–2525. https://doi.org/10.1007/s00198-022-06549-x
doi: 10.1007/s00198-022-06549-x
pubmed: 36115888
pmcid: 9652244